Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine. The poster, released as part ...

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials, the pharma’s head of metabolism R&D has told Fierce Biotech.

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the trial sent shares tumbling on Monday. “We’re not alarmed at all ...

Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later ...

Square Enix producer Yoshinori Kitase promised fans of the original Final Fantasy 7 that they won’t feel betrayed by FF7 Remake Part 3. Kitase made the comments to Anime News Network in response ...

FRANKFURT, Sept 11 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July ...

ASX chairman Damian Roche will retire next month after four years as head of the board of the sharemarket operator, a period marked by the failed roll-out of critical settlement and clearing ...

Please verify your email address. With the unveiling of the PS5 Pro came the reveal that Final Fantasy 7 Rebirth would be enhanced, suggesting big things for the third game. Would Square Enix ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).